Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder

16 november 2026 uppdaterad av: Stephanie M Gorka, PhD, Ohio State University

The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users.

The main questions it aims to answer are:

  • Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
  • Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)?

Participants will:

  • Complete a screening session
  • Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety
  • Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and pain-related negative affect

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

90

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

ALC Only Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)

OUD + ALC Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
  • Meet DSM-5 criteria for current opioid use disorder (OUD)
  • Report using recreational opioids at least weekly (past month)

OUD-ALC Group:

  • 21-65 years old
  • Meet DSM-5 criteria for current OUD
  • Report using recreational opioids at least weekly (past month)
  • Meet "light drinking" criteria (consuming equal to or less than 4 drinks per week for women or consuming equal to or less than 5 drinks per week for men)
  • Report at least 1 but no more than 3 binge episodes over the past 12 months

Exclusion Criteria:

  • Serious medical problems
  • Current medical or psychiatric conditions requiring medication for which alcohol is contraindicated (including prescription opioids)
  • Any serious medical problems
  • Sensitivity or allergy to alcohol
  • Body weight < 110 or > 210 lbs for alcohol administration
  • Injury, trauma, nerve/tissue damage, or deformity prohibiting sensory testing
  • Moderate to severe substance use disorders other than alcohol use disorder (AUD) or OUD
  • Current severe mental illness, including mania or psychosis
  • Currently seeking inpatient/intensive treatment for addictive behaviors
  • Pregnant or nursing and unwilling to take measures to avoid becoming pregnant during the study (females)
  • Chronic pain requiring ongoing pain management within the past three months.
  • Clinically significant alcohol or opioid withdrawal symptoms the day of the lab sessions, defined as a score >10 on the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) or a score >12 on the Clinical Opioid Withdrawal Scale (COWS)
  • Positive alcohol breath test or opioid urine screen the day of the experimental lab sessions to avoid the potential for alcohol-opioid interactions.
  • Smoking more than 6 cigarettes per day (or alternative form equivalent)
  • Not fluent in English

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Alcohol (ALC) Only Group

Participants in this group will be required to meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week).

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

Övrig: Opioid Use Disorder (OUD) + ALC Group

Participants in this group will be required to 1) Meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week); 2) Meet DSM-5 criteria for current OUD and; 3) Report using recreational opioids at least weekly (past month).

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

Övrig: OUD-ALC Group

Participants in this group will be required to 1) Meet DSM-5 criteria for current OUD; 2) Report using recreational opioids at least weekly (past month); 3) Meet "light drinking" criteria (consuming less than or equal to 4 alcoholic drinks per week (female) or less than or equal to 5 alcoholic drinks (men) and; 4) Report at least 1 but no more than 3 binge episodes over the past 12 months.

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain intensity during the pressure task, measured using a visual analog scale (VAS)
Tidsram: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Pain intensity will be reported during the pressure task administered during each of the three laboratory sessions (Baseline, Placebo, and Alcohol). Participants will rate their perceived pain intensity using a numerical rating scale ranging from 0-100.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Pain pressure threshold during the pressure task
Tidsram: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Pain pressure threshold is estimated by averaging reports across the different runs of the pressure task that is administered at all three lab sessions.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Startle eyeblink potentiation during the anticipation task
Tidsram: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Startle eyeblink potentiation will be collected during the anticipation task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Self-reported affect during the anticipation task
Tidsram: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

At the end of the anticipation task, participants will rate how intense, arousing, and anxiety-provoking the task was on a 1-to-10 scale, with 1 indicating low intensity, arousal, or anxiety and 10 indicating high intensity, arousal, or anxiety.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Subjective affective response to alcohol in the lab
Tidsram: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The individual mood states will be examined and compared across sessions. Higher scores on each POMS subscale indicate a greater degree of the corresponding mood state, while lower scores indicate a lesser degree of that mood state.

Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Subjective effects of alcohol in the lab
Tidsram: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will rate the degree to which they "feel", "like", and "want more" of the infused substance on a visual analog scale ranging from 0 to 100. The "like" and "want more" scales will serve as the primary measures of alcohol liking and wanting, respectively.

Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 november 2026

Primärt slutförande (Beräknad)

1 augusti 2028

Avslutad studie (Beräknad)

1 augusti 2028

Studieregistreringsdatum

Först inskickad

16 september 2026

Först inskickad som uppfyllde QC-kriterierna

19 oktober 2026

Första postat (Faktisk)

26 oktober 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.

Tidsram för IPD-delning

The data will be submitted biannually.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera